Zevra Therapeutics
Price & Volume
Stats
See more52W Range | $7.16-$13.16 |
Market Cap | $650.2M |
Shares Short | 4M |
Financials
See moreRevenue (12 Mos) | $106.4M |
Revenue Growth (YoY) | 183.4% |
Gross Profit (12 Mos) | $89.9M |
Diluted EPS | $1.35 |
News
See moreYahoo Finance • 2 months ago
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Yahoo Finance • 2 months ago
Zevra Turns Profitable In 2025 On Strong Uptake Of MIPLYFFA For Niemann-Pick Disease Type C
Yahoo Finance • 3 months ago
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
Yahoo Finance • 3 months ago
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
About
CEO | Mr. Neil F. McFarlane |
CFO | Mr. Justin A. Renz CPA, MBA |
Address | 101 Federal Street, Boston, MA, United States, 02110 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 61 |